Ilya Rachman
Director Ejecutivo en IMMIX BIOPHARMA, INC. .
Fortuna: 2 M $ al 30/04/2024
Cargos activos de Ilya Rachman
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| IMMIX BIOPHARMA, INC. | Director Ejecutivo | 01/01/2012 | - |
| Presidente | 01/01/2012 | - | |
| Fundador | 01/01/2012 | - | |
Nexcella, Inc.
 Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Presidente | - | - |
Historial de carrera de Ilya Rachman
Formación de Ilya Rachman.
| University of Illinois | Doctorate Degree |
| University of Iowa | Undergraduate Degree |
| University of California, Los Angeles | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 6 |
Operativa
| Chairman | 2 |
| Chief Executive Officer | 1 |
| Founder | 1 |
Sectorial
| Consumer Services | 4 |
| Health Technology | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| IMMIX BIOPHARMA, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |
- Bolsa de valores
- Insiders
- Ilya Rachman
- Experiencia